Alkermes reported second quarter 2026 revenue of $496.0 million on July 28, a 27 percent jump from the $390.7 million it booked in the same quarter of 2025, and the print lands as the first full quarter of consolidation following the $21.00-per-share acquisition of Avadel Pharmaceuticals that closed on February 12, 2026. The headline is deceptively clean because the GAAP net income of $0.5 million, essentially breakeven on 167.0 million basic shares, hides a quarter dominated by one-time deal charges and a non-cash remeasurement of the Avadel contingent value right. The underlying commercial story is that every legacy proprietary product grew, and the freshly acquired LUMRYZ added $96.6 million in its first full quarter under Alkermes ownership, transforming a mature neuroscience portfolio into a genuine growth compound with an orexin pipeline attached.
The thesis rests on the notion that the market underweights the optionality embedded in Alkermes' orexin 2 receptor agonist portfolio, anchored by alixorexton for narcolepsy, while the base business throws off enough cash to fund the build. The company exited 2025 as a free-standing operator with $241.7 million of GAAP net income from continuing operations, then used its balance sheet to purchase Avadel and its one-and-done nightly sodium oxybate product, LUMRYZ, for narcolepsy. That acquisition stacks a second commercial asset on top of VIVITROL, ARISTADA and LYBALVI while simultaneously delivering a ready-made sleep-medicine sales force and an early-stage orexin franchise that includes candidates aimed at idiopathic hypersomnia, ADHD and fatigue. We read the second quarter as the moment the rebuilt platform became observable: revenue accelerated, adjusted EBITDA rose to $139.2 million from $126.5 million a year earlier, and management held full-year adjusted EBITDA guidance at $370 million to $410 million even as it absorbed the full cost of the deal.
The single load-bearing risk is that the leverage model breaks before the orexin payoff arrives. Alkermes carried $1.525 billion of secured term loans at June 30, 2026, a step onto the balance sheet of a company that had eliminated all long-term debt just two years earlier, and the interest bill is now a permanent feature of the income statement. The falsifiable clock runs through the remainder of 2026: first ADHD data for ALKS 7290 lands in the coming months, topline results from the Vibrance-3 phase 2 study of alixorexton in idiopathic hypersomnia are expected toward year-end, and any stumble in LUMRYZ execution tests whether the heavily marked-up inventory that purchase accounting placed on the balance sheet translates into the revenue growth the valuation assumes.